Decision Making for Older Adults With Cancer

You may be eligible if

• 1. Independently practicing medical oncology physician (non-ACGME oncology fellows who practice independently are eligible).
• 2. Annually care for at least 10 patients age \>=65 years with solid tumor malignancies in the outpatient setting (this criterion will be confirmed by oncologist report).
• 3. Willing to complete the two-hour intervention training.
• 4. At the time of enrollment, plans to continue outpatient practice at a University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center (HDFCCC) affiliated site for the duration of the pilot study.
• 1. Age \>= 65 years.
• 2. Diagnosed with a solid tumor malignancy of any stage.
• 3. 3\. Upcoming decision-making discussion (in-person or via video conferencing) with a participating medical oncologist.
• 4. Able to read, write, and understand English.
• 5. Able to understand and provide written, informed consent. Adequate decisional capacity to consent for this study will be determined using the UCSF Decision-Making Capacity Assessment Tool. Patients with mild cognitive impairment who have adequate decisional capacity to consent for this study will be included.
• There are no performance status, organ function, or comorbidity eligibility criteria for this study.
• During the CRT phase, patients will be given the option to select a caregiver to participate in the study (not required). Caregivers cannot participate without an enrolled patient. Caregivers may be a family member, partner, or friend of the participating patient.
• 1. Age \>=18 years.
• 2. Must plan to be present during the medical oncology decision-making discussion and follow-up visits within the first 3 months.
• 3. Able to read, write, and understand English.
• 4. Able to understand and provide written, informed consent.
• 2. Planned decision-making discussion via phone only (without video).
• 3. Patients participating in another cancer communication/decision support intervention study with their medical oncologist.